Renfeng Guo
Oprichter bij INFLARX N.V.
Vermogen: 3 M $ op 31-05-2024
Profiel
Renfeng Guo founded InflaRx GmbH in 2007, where he worked as Chief Scientific Officer from 2009 to 2012 and InflaRx NV in 2007, where he is working as Executive Director & Chief Scientific Officer from 2007.
Dr. Guo also formerly worked at the University of Michigan, as Associate Professor.
Dr. Guo received his doctorate degree from Norman Bethune Medical University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
INFLARX N.V.
2.99% | 31-12-2023 | 1 762 144 ( 2.99% ) | 3 M $ | 31-05-2024 |
Actieve functies van Renfeng Guo
| Bedrijven | Functie | Begin |
|---|---|---|
| INFLARX N.V. | Oprichter | 01-12-2007 |
Eerdere bekende functies van Renfeng Guo
| Bedrijven | Functie | Einde |
|---|---|---|
| University of Michigan | Corporate Officer/Principal | - |
InflaRx GmbH
 InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Oprichter | - |
Opleiding van Renfeng Guo
| Norman Bethune Medical University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INFLARX N.V. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Health Technology |
